Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1980
Report date:
1980

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 402 (Acute Dermal Toxicity)
Deviations:
yes
Remarks:
occlusive coverage
GLP compliance:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
p-[(2-chloroethyl)ethylamino]benzaldehyde
EC Number:
220-150-2
EC Name:
p-[(2-chloroethyl)ethylamino]benzaldehyde
Cas Number:
2643-07-4
Molecular formula:
C11H14ClNO
IUPAC Name:
4-[(2-chloroethyl)(ethyl)amino]benzaldehyde
Details on test material:
N-Ethyl-N-(2-chlorethyl)-p-amino-benzaldehyd (purity> 90 %)

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female

Administration / exposure

Type of coverage:
occlusive
Vehicle:
other: no vehicle or aqua dest.
Details on dermal exposure:
TEST SITE
- Area of exposure: 50 cm²

Duration of exposure:
24 h
Doses:
200, 400, 1000, 1470, 2000, 2610, 3160, 4640 mg/kg bw
No. of animals per sex per dose:
5
Control animals:
not specified
Details on study design:
- Duration of observation period following administration: 14 days

Results and discussion

Effect levelsopen allclose all
Sex:
female
Dose descriptor:
LD50
Effect level:
1 630 mg/kg bw
Sex:
male
Dose descriptor:
LD50
Effect level:
> 4 600 mg/kg bw
Mortality:
Mortality was observed in the dose 4640, 3160, 2610, 2000, 1470 mg/kg b.w.
Clinical signs:
other: dyspnea, apathy, excitation, abdominal position, staggering, atonia, tremor, spastic gait, saltation convulsions, bite convulsions, tonic convulsions, tonic-clonic convulsions, anemic paleness, poor general state, piloerrection
Gross pathology:
Dead animals: heart: dilatation right side; acute congestive hyperemia; liver: almost loamy grey due to broadened grey hepatic lobules
Sacrificed animals: nothing abnormal detected
Other findings:
LOCAL SKIN IRRITATIONS:
4640 mg/kg bw: after 24 h slight erythema, slight edema, after 7 days nothing abnormal detected
3160 mg/kg bw: after 24 h questionable slight erythema, slight edema, after 7 days partial scaling, after 13 days yellow substance residuals (male animals), female animals after 13 days: no abnormality detected
2610 mg/kg bw: after 24 h questionable slight erythema, slight edema, after 7 days nothing abnormal detected
2000 mg/kg bw: after 24 h slight erythema, slight edema, after 7 days scaling, after that nothing abnormal detected
1470 mg/kg bw: after 24 h questionable erythema, very slight edema, after 7 days nothing abnormal detected
1000 mg/kg bw: after 24 h slight edema, strong edema, after 7 days nothing abnormal detected
400 mg/kg bw: after 24 h slight erythema, slight edema, after 7 days nothing abnormal detected
200 mg/kg bw: after 24 h questionable erythema, slight edema, after 7 days nothing abnormal detected

Any other information on results incl. tables

Mortality data:

Dose (mg/kg)

Conc. (%)

No. of animals

died within

1 hour

24 hours

48 hours

7 days

14 days

4640

100

4 males

0/4

1/4

1/4

1/4

1/4

4640

100

5 females

0/5

4/5

4/5

5/5

5/5

3160

100

4 males

0/4

0/4

0/4

0/4

0/4

3160

100

5 females

0/5

3/5

3/5

3/5

3/5

2610

100

5 males

0/5

0/5

0/5

1/5

1/5

2610

100

5 females

0/5

3/5

3/5

3/5

3/5

2000

100

5 males

0/5

0/5

0/5

0/5

0/5

2000

100

5 females

0/5

1/5

2/5

3/5

3/5

1470

100

5 males

0/5

0/5

0/5

0/5

0/5

1470

100

5 females

0/5

4/5

4/5

4/5

4/5

1000

100

5 males

0/5

0/5

0/5

0/5

0/5

1000

100

5 females

0/5

1/5

1/5

1/5

1/5

400

50

5 males

0/5

0/5

0/5

0/5

0/5

400

50

5 females

0/5

0/5

0/5

0/5

0/5

200

25

5 males

0/5

0/5

0/5

0/5

0/5

200

25

5 females

0/5

0/5

0/5

0/5

0/5

 

Applicant's summary and conclusion